胸腺切除范围对早期胸腺上皮肿瘤预后的影响

背景与目的探采用中国胸腺肿瘤协作组胸腺肿瘤多中心回顾性数据库,探讨胸腺切除范围对早期胸腺上皮肿瘤预后的影响。方法选择Masaoka-Koga分期I期、II期且术前没有接受新辅助治疗的患者,根据术中胸腺切除程度,分为胸腺切除组及胸腺瘤切除组。对比分析两组患者的临床特点及预后差异。结果共有1,047例患者纳入研究,其中胸腺切除组入组796例患者、胸腺瘤切除组入组251例患者。对于术前合并重症肌无力(my-asthenia gravis, MG)的患者,胸腺切除组术后的MG的缓解率明显优于胸腺瘤切除组(91.6%vs 50.0%,P<0.001)。胸腺切除组的10年总体生存率(overall sur...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 19; no. 7; pp. 459 - 464
Main Author 谷志涛 傅剑华 沈毅 魏煜程 谭黎杰 张鹏 韩泳涛 陈椿 张仁泉 李印 陈克能 陈和忠 刘永煜 崔有斌 王允 庞烈文 于振涛 周鑫明 柳阳春 刘媛 方文涛
Format Journal Article
LanguageChinese
Published 上海交通大学附属上海胸科医院,上海,200030%中山大学附属肿瘤医院胸外科,广州,510060%266001青岛大学医学院附属医院胸外科%复旦大学附属中山医院胸外科,上海,200032%天津医科大学附属总医院胸外科,天津,300052%610041成都,四川省肿瘤医院胸外科,马可%福建医科大学附属协和医院胸外科,福州,350001%安徽医科大学附属第一医院胸外科,合肥,230022%郑州大学附属肿瘤医院胸外科,郑州,450008%北京大学附肿瘤医院胸外科,北京,100142%长海医院胸心外科,上海,200433%辽宁肿瘤医院胸外科,沈阳,110042%吉林大学附属第一医院胸外科,长春,130021%四川大学华西医院胸外科,成都,610041%复旦大学附属华山医院胸外科,上海,200032%天津医科大学附属肿瘤医院食管癌中心,天津,300060%浙江省肿瘤医院胸外科,杭州,310022%江西省人民医院胸外科,南昌,330006 2016
Subjects
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2016.07.08

Cover

Abstract 背景与目的探采用中国胸腺肿瘤协作组胸腺肿瘤多中心回顾性数据库,探讨胸腺切除范围对早期胸腺上皮肿瘤预后的影响。方法选择Masaoka-Koga分期I期、II期且术前没有接受新辅助治疗的患者,根据术中胸腺切除程度,分为胸腺切除组及胸腺瘤切除组。对比分析两组患者的临床特点及预后差异。结果共有1,047例患者纳入研究,其中胸腺切除组入组796例患者、胸腺瘤切除组入组251例患者。对于术前合并重症肌无力(my-asthenia gravis, MG)的患者,胸腺切除组术后的MG的缓解率明显优于胸腺瘤切除组(91.6%vs 50.0%,P<0.001)。胸腺切除组的10年总体生存率(overall survival, OS)为90.9%,胸腺瘤切除组的10年OS为89.4%,两者之间没有统计学差异(P=0.732)。胸腺切除组术后复发率为3.7%,胸腺瘤切除组术后复发率为6.2%,两组之间无统计学差异(P=0.149)。进一步分层分析显示,对于Masaoka-Koga I期患者,胸腺切除组和胸腺瘤切除组在复发率上没有差异(3.2%vs 1.4%,P=0.259);然而在Masaoka-Koga II期患者中,胸腺切除组的复发率明显低于胸腺瘤切除组的复发率(2.9%vs 14.5%,P=0.001)。结论胸腺切除是治疗胸腺上皮肿瘤的标准手术方式,特别是对于Masaoka-Koga II期及合并MG的患者。
AbstractList 背景与目的探采用中国胸腺肿瘤协作组胸腺肿瘤多中心回顾性数据库,探讨胸腺切除范围对早期胸腺上皮肿瘤预后的影响。方法选择Masaoka-Koga分期I期、II期且术前没有接受新辅助治疗的患者,根据术中胸腺切除程度,分为胸腺切除组及胸腺瘤切除组。对比分析两组患者的临床特点及预后差异。结果共有1,047例患者纳入研究,其中胸腺切除组入组796例患者、胸腺瘤切除组入组251例患者。对于术前合并重症肌无力(my-asthenia gravis, MG)的患者,胸腺切除组术后的MG的缓解率明显优于胸腺瘤切除组(91.6%vs 50.0%,P<0.001)。胸腺切除组的10年总体生存率(overall survival, OS)为90.9%,胸腺瘤切除组的10年OS为89.4%,两者之间没有统计学差异(P=0.732)。胸腺切除组术后复发率为3.7%,胸腺瘤切除组术后复发率为6.2%,两组之间无统计学差异(P=0.149)。进一步分层分析显示,对于Masaoka-Koga I期患者,胸腺切除组和胸腺瘤切除组在复发率上没有差异(3.2%vs 1.4%,P=0.259);然而在Masaoka-Koga II期患者中,胸腺切除组的复发率明显低于胸腺瘤切除组的复发率(2.9%vs 14.5%,P=0.001)。结论胸腺切除是治疗胸腺上皮肿瘤的标准手术方式,特别是对于Masaoka-Koga II期及合并MG的患者。
背景与目的探采用中国胸腺肿瘤协作组胸腺肿瘤多中心回顾性数据库,探讨胸腺切除范围对早期胸腺上皮肿瘤预后的影响。方法选择Masaoka-Koga分期I期、II期且术前没有接受新辅助治疗的患者,根据术中胸腺切除程度,分为胸腺切除组及胸腺瘤切除组。对比分析两组患者的临床特点及预后差异。结果共有1,047例患者纳入研究,其中胸腺切除组入组796例患者、胸腺瘤切除组入组251例患者。对于术前合并重症肌无力(my-asthenia gravis, MG)的患者,胸腺切除组术后的MG的缓解率明显优于胸腺瘤切除组(91.6%vs 50.0%,P<0.001)。胸腺切除组的10年总体生存率(overall survival, OS)为90.9%,胸腺瘤切除组的10年OS为89.4%,两者之间没有统计学差异(P=0.732)。胸腺切除组术后复发率为3.7%,胸腺瘤切除组术后复发率为6.2%,两组之间无统计学差异(P=0.149)。进一步分层分析显示,对于Masaoka-Koga I期患者,胸腺切除组和胸腺瘤切除组在复发率上没有差异(3.2%vs 1.4%,P=0.259);然而在Masaoka-Koga II期患者中,胸腺切除组的复发率明显低于胸腺瘤切除组的复发率(2.9%vs 14.5%,P=0.001)。结论胸腺切除是治疗胸腺上皮肿瘤的标准手术方式,特别是对于Masaoka-Koga II期及合并MG的患者。
Abstract_FL Background and objectiveTo evaluate the surgical outcomes of tumor resection with or without total thymectomy for thymic epithelial tumors (TETs) using the Chinese Alliance for Research in Thymomas (ChART) retrospec-tive database.Methods Patients without preoperative therapy, who underwent surgery for early-stage (Masaoka-Koga stage I and II) tumors, were enrolled for the study. They were divided into thymectomy and thymomectomy groups according to the resection extent of the thymus. Demographic and surgical outcomes were compared between the two patients groups. Results A total of 1,047 patients were enrolled, with 796 cases in the thymectomy group and 251 cases in the thymomec-tomy group. Improvement rate of myasthenia gravis (MG) was higher atfer thymectomy than atfer thymomectomy (91.6%vs 50.0%,P<0.001). Ten-year overall survival was similar between the two groups (90.9% atfer thymectomy and 89.4% atfer thymomectomy,P=0.732). Overall, recurrence rate was 3.1% atfer thymectomy and 5.4% atfer thymomectomy, with no sig-niifcant difference between the two groups (P=0.149). Stratiifed analysis revealed no signiifcant difference in recurrence rates in Masaoka-Koga stage I tumors (3.2%vs 1.4%,P=0.259). However in patients with Masaoka-Koga stage II tumors, recurrence was signiifcantly less atfer thymectomy group than atfer thymomectomy (2.9%vs 14.5%,P=0.001).Conclusion hTymectomy, instead of tumor resection alone, should still be recommended as the surgical standard for thymic malignancies, especially for stage II tumors and those with concomitant MG.
Author 谷志涛 傅剑华 沈毅 魏煜程 谭黎杰 张鹏 韩泳涛 陈椿 张仁泉 李印 陈克能 陈和忠 刘永煜 崔有斌 王允 庞烈文 于振涛 周鑫明 柳阳春 刘媛 方文涛
AuthorAffiliation 上海交通大学附属上海胸科医院,上海200030 中山大学附属肿瘤医院胸外科,广州510060 青岛大学医学院附属医院胸外科,266001 复旦大学附属中山医院胸外科,上海200032 天津医科大学附属总医院胸外科,天津300052 四川省肿瘤医院胸外科,成都 610041 福建医科大学附属协和医院胸外科,福州350001 安徽医科大学附属第一医院胸外科,合肥230022 郑州大学附属肿瘤医院胸外科,郑州450008 北京大学附肿瘤医院胸外科,北京100142 长海医院胸心外科,上海200433 辽宁肿瘤医院胸外科,沈阳110042 吉林大学附属第一医院胸外科,长春130021 四川大学华西医院胸外科,成都610041 复旦大学附属华山医院胸外科,上海200032 天津医科大学附属肿瘤医院食管癌中心,天津300060 浙江省肿瘤医院胸外科,杭州310022 江西省人民医院胸外科,南昌330006
AuthorAffiliation_xml – name: 上海交通大学附属上海胸科医院,上海,200030%中山大学附属肿瘤医院胸外科,广州,510060%266001青岛大学医学院附属医院胸外科%复旦大学附属中山医院胸外科,上海,200032%天津医科大学附属总医院胸外科,天津,300052%610041成都,四川省肿瘤医院胸外科,马可%福建医科大学附属协和医院胸外科,福州,350001%安徽医科大学附属第一医院胸外科,合肥,230022%郑州大学附属肿瘤医院胸外科,郑州,450008%北京大学附肿瘤医院胸外科,北京,100142%长海医院胸心外科,上海,200433%辽宁肿瘤医院胸外科,沈阳,110042%吉林大学附属第一医院胸外科,长春,130021%四川大学华西医院胸外科,成都,610041%复旦大学附属华山医院胸外科,上海,200032%天津医科大学附属肿瘤医院食管癌中心,天津,300060%浙江省肿瘤医院胸外科,杭州,310022%江西省人民医院胸外科,南昌,330006
Author_FL Hezhong CHEN
Chun CHEN
Youbing CUI
Yuan LIU
Jianhua FU
Lijie TAN
Yin LI
Xinming ZHOU
Renquan ZHANG
Zhentao YU
Yi SHEN
Liewen PANG
Yucheng WEI
Yongyu LIU
Yun WANG
Zhitao GU
Yangchun LIU
Yongtao HAN
Ke-Neng CHEN
Peng ZHANG
Wentao FANG
Author_FL_xml – sequence: 1
  fullname: Zhitao GU
– sequence: 2
  fullname: Jianhua FU
– sequence: 3
  fullname: Yi SHEN
– sequence: 4
  fullname: Yucheng WEI
– sequence: 5
  fullname: Lijie TAN
– sequence: 6
  fullname: Peng ZHANG
– sequence: 7
  fullname: Yongtao HAN
– sequence: 8
  fullname: Chun CHEN
– sequence: 9
  fullname: Renquan ZHANG
– sequence: 10
  fullname: Yin LI
– sequence: 11
  fullname: Ke-Neng CHEN
– sequence: 12
  fullname: Hezhong CHEN
– sequence: 13
  fullname: Yongyu LIU
– sequence: 14
  fullname: Youbing CUI
– sequence: 15
  fullname: Yun WANG
– sequence: 16
  fullname: Liewen PANG
– sequence: 17
  fullname: Zhentao YU
– sequence: 18
  fullname: Xinming ZHOU
– sequence: 19
  fullname: Yangchun LIU
– sequence: 20
  fullname: Yuan LIU
– sequence: 21
  fullname: Wentao FANG
Author_xml – sequence: 1
  fullname: 谷志涛 傅剑华 沈毅 魏煜程 谭黎杰 张鹏 韩泳涛 陈椿 张仁泉 李印 陈克能 陈和忠 刘永煜 崔有斌 王允 庞烈文 于振涛 周鑫明 柳阳春 刘媛 方文涛
BookMark eNo1j81Kw0AUhQepYFt9CV24SpyZO5nJgBsp_kHBTfdlkiY1QafaIGKWtqKIiuBCrYIg3bhRBBdVEF_GNOlbGKmuzoHzce49JVTQLe0hNEewCULIhdAMokibBGNpACPSpJhwEwsT2xOoSKSUBie2KOT-H5lCpSgKMeZUAiuixawzyI4-kpPj0W0_O-skd2_Jy_vw-ml4_zCOvgenae85O_xKb_qjx25yeZH2usnna3J1Po0mfbUVeTN_Wka1leVaZc2obqyuV5aqhmvlH7iiQT3H5pIwTh0JlHGwJFG-S20QnNqcehzAEo6gDIAxxyMebXACylLCFlBG8-PafaV9pZv1sLXX1vnBetz0VRz_jsYiH5iTs2PS3Wzp5m6QszvtYFu1D-qcSwDMGIMfKZdtwQ
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3779/j.issn.1009-3419.2016.07.08
DatabaseName 维普期刊资源整合服务平台
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Thymectomy versus Tumor Resection for Early-stage Thymic Malignancies:A Chi-nese Alliance for Research in Thymomas (ChART) Retrospective Database Analysis
DocumentTitle_FL Thymectomy versus Tumor Resection for Early-stage Thymic Malignancies:A Chi-nese Alliance for Research in Thymomas (ChART) Retrospective Database Analysis
EISSN 1999-6187
EndPage 464
ExternalDocumentID zgfazz201607009
669330444
GroupedDBID ---
-05
04C
29R
2B.
2C~
2RA
2WC
3V.
5GY
5VS
6PF
92F
92I
92L
AAWTL
ABUWG
ACGFS
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVBZV
C1A
CCEZO
CCPQU
CIEJG
CQIGP
CW9
DIK
E3Z
EBD
EIHBH
EMOBN
EOJEC
F5P
GROUPED_DOAJ
HYE
IPNFZ
KQ8
KWQ
OBODZ
OK1
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
PGMZT
PHGZM
PHGZT
PMFND
PSX
ID FETCH-LOGICAL-c599-c7d2eb8691462b932463591afc283762862e63357b7243344be1e2d613a5a7873
ISSN 1009-3419
IngestDate Thu May 29 03:56:17 EDT 2025
Wed Feb 14 10:18:05 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Thymic epithelial tumors
Myasthenia gravis
胸腺瘤切除
hTymectomy
胸腺上皮肿瘤
重症肌无力
胸腺切除
hTymomectomy
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c599-c7d2eb8691462b932463591afc283762862e63357b7243344be1e2d613a5a7873
Notes Background and objectiveTo evaluate the surgical outcomes of tumor resection with or without total thymectomy for thymic epithelial tumors (TETs) using the Chinese Alliance for Research in Thymomas (ChART) retrospec-tive database.Methods Patients without preoperative therapy, who underwent surgery for early-stage (Masaoka-Koga stage I and II) tumors, were enrolled for the study. They were divided into thymectomy and thymomectomy groups according to the resection extent of the thymus. Demographic and surgical outcomes were compared between the two patients groups. Results A total of 1,047 patients were enrolled, with 796 cases in the thymectomy group and 251 cases in the thymomec-tomy group. Improvement rate of myasthenia gravis (MG) was higher atfer thymectomy than atfer thymomectomy (91.6%vs 50.0%,P〈0.001). Ten-year overall survival was similar between the two groups (90.9% atfer thymectomy and 89.4% atfer thymomectomy,P=0.732). Overall, recurrence rate was 3.1% atfer thymectomy and 5.4% atfer thymomectomy,
PageCount 6
ParticipantIDs wanfang_journals_zgfazz201607009
chongqing_primary_669330444
PublicationCentury 2000
PublicationDate 2016
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – year: 2016
  text: 2016
PublicationDecade 2010
PublicationTitle 中国肺癌杂志
PublicationTitleAlternate Chinese Journal of Lung Cancer
PublicationYear 2016
Publisher 上海交通大学附属上海胸科医院,上海,200030%中山大学附属肿瘤医院胸外科,广州,510060%266001青岛大学医学院附属医院胸外科%复旦大学附属中山医院胸外科,上海,200032%天津医科大学附属总医院胸外科,天津,300052%610041成都,四川省肿瘤医院胸外科,马可%福建医科大学附属协和医院胸外科,福州,350001%安徽医科大学附属第一医院胸外科,合肥,230022%郑州大学附属肿瘤医院胸外科,郑州,450008%北京大学附肿瘤医院胸外科,北京,100142%长海医院胸心外科,上海,200433%辽宁肿瘤医院胸外科,沈阳,110042%吉林大学附属第一医院胸外科,长春,130021%四川大学华西医院胸外科,成都,610041%复旦大学附属华山医院胸外科,上海,200032%天津医科大学附属肿瘤医院食管癌中心,天津,300060%浙江省肿瘤医院胸外科,杭州,310022%江西省人民医院胸外科,南昌,330006
Publisher_xml – name: 上海交通大学附属上海胸科医院,上海,200030%中山大学附属肿瘤医院胸外科,广州,510060%266001青岛大学医学院附属医院胸外科%复旦大学附属中山医院胸外科,上海,200032%天津医科大学附属总医院胸外科,天津,300052%610041成都,四川省肿瘤医院胸外科,马可%福建医科大学附属协和医院胸外科,福州,350001%安徽医科大学附属第一医院胸外科,合肥,230022%郑州大学附属肿瘤医院胸外科,郑州,450008%北京大学附肿瘤医院胸外科,北京,100142%长海医院胸心外科,上海,200433%辽宁肿瘤医院胸外科,沈阳,110042%吉林大学附属第一医院胸外科,长春,130021%四川大学华西医院胸外科,成都,610041%复旦大学附属华山医院胸外科,上海,200032%天津医科大学附属肿瘤医院食管癌中心,天津,300060%浙江省肿瘤医院胸外科,杭州,310022%江西省人民医院胸外科,南昌,330006
SSID ssj0062934
ssib002262905
ssib044765436
ssib001103766
ssib038074678
ssib051369142
Score 2.0777266
Snippet 背景与目的探采用中国胸腺肿瘤协作组胸腺肿瘤多中心回顾性数据库,探讨胸腺切除范围对早期胸腺上皮肿瘤预后的影响。方法选择Masaoka-Koga分期I期、II期且术前没有接受新辅助...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 459
SubjectTerms 胸腺上皮肿瘤
胸腺切除
胸腺瘤切除
重症肌无力
Title 胸腺切除范围对早期胸腺上皮肿瘤预后的影响
URI http://lib.cqvip.com/qk/91098A/201607/669330444.html
https://d.wanfangdata.com.cn/periodical/zgfazz201607009
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: KQ8
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ DIrectory of Open Access Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DOA
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib044765436
  issn: 1009-3419
  databaseCode: M~E
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central [Accès libre]
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: East & South Asia Database (ProQuest)
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BVBZV
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eastsouthasia
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BENPR
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV3NixxFFG_iBoIg4ifGaFjQOk6crq5P8NLV00MQEkRWyG2Zr97kMkk0uczRRAxBRfCgRkGQXLwogocoiP-Mk938F773qrq6d3bc3ZmE4GWo6ap-71fvq6qrul8lydtiMuDZUNhOOhiOOqLKxuBStupMcMuoq8bZWOPHyRcuqvMfivcuyUsnnpOtt5Zu3hieG82WfleyjlbhGugVv5JdQbORKFyAMugXfkHD8HssHbPSMJMxZ6ggmctZKZmBsmalZdayXFBVgc2gyjrmBBbyPnOWlYpZzXJfKJjtLyMo8K-BgmY2Z3lJVZy5Pl0xxAIYcWaIsu0yU4bG_orrMZdSVcZMrz0bDsTzXo2tVxP37CwiR2w9vIik-szGgRPbui5zOtZgWwfNXdNE4p3QEyyARAiHAXJl0wTu4Sg0KIBY_NE-vsYiNEMdBRIgISjkANC110r8R5xk1y1hAVFJ0AR2xssIXyohDcHfnFAD-VwFVQVhpcyWy-hExWi8N3SkYM7VmubgLUtu5AWnJ1LG5T5xAyOvlaPBHNT3AdYNPCJoVYMTUUm0NqRAkCy-gQtRuqsQFczd8BwHJNVj1quZozUswRb57keLAA7CXgmkDBfBNoJXqBU0tSDS1YTzXyrjDSrvouC6uWzRb1nC0TgVmp8X3aq6WwDAi4y27gGewkyQKRE36Plo5Bm5McSXgryXHNtrE1XfIyuCqvRx7aphYRFeTrzAWcGHUW6kQeNNztWRcQ25-XBBdMA4fY9WE2AbSTD-DA-IiVZXYmjC2pJEtx5OjRLIozl111E0xm4T9EKK5hk-fRFO0qwH43vxlELHAb68ECg9E6QH1GwMs8WhqJ5EHFtgxwvMLihqEVkaiJqgfSh9aOlH5WPHBIH7opLGvdpU0Hge25V40RoFLVJwGXYNvbuOQmgbfqJQkgSejk22RIr9QpvEN2N47TuLsWXpkNGjGQnd7segVSWzENx4EeLe-qNGRPU_HzWOY1fwm9HcUaM15mlr6tYeHMnaDxlQlJ-iUHesr00D2ScyXvB6Khnw1KE4jSEucoymElmTvzsv7e7y2dfRoaMXpqiWZuTAmrrdWhbAV4gw8_G-dQPbej7SrUUAEc648etJwp_Ss7hUgYm-aakCGZyLDPBjE3-cgGlWaOJ3M7OdajCbccoKTWlLTnLchtxITrry4vsfNOugmP2jvS_DFbfNgz0eMiVUk8dXCI0pZmJ7mWbKpiLm4YWb_eu5NcpTyVuhC-8c0gFMV3f56nTn-pXpDuVEmFaD6U5r-W7rheT5sO6-mfuHqBeTE7PLLyWnLoQ3i19O3t279WDv0z_ndz579N39vc9vzb__ff7rHw-_-fnhDz_6qn8e3N2998veJ3_vfnv_0U-35199uXvv9vyv3-Zff_FKstUvt4rznXCyXGckre2M9JhPhgb7qPjQZlyoTNp0UI0wFygm6-ETlWVSDzWHyC7EcJJO-Fil2UAOtNHZq8nG9Op08lqyqbkxuASuR7wSemCNGstuVcmKp-OR5qPTyZkog-1rPoHgtlK0jSzE6WQzSGU7PFZ-vL2g49ePbnImeRbLfmP4jWTjxkc3J28mz8Bz9NlgGGdpq_FfLbidkg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E8%83%B8%E8%85%BA%E5%88%87%E9%99%A4%E8%8C%83%E5%9B%B4%E5%AF%B9%E6%97%A9%E6%9C%9F%E8%83%B8%E8%85%BA%E4%B8%8A%E7%9A%AE%E8%82%BF%E7%98%A4%E9%A2%84%E5%90%8E%E7%9A%84%E5%BD%B1%E5%93%8D&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%82%BA%E7%99%8C%E6%9D%82%E5%BF%97&rft.au=%E8%B0%B7%E5%BF%97%E6%B6%9B&rft.au=%E5%82%85%E5%89%91%E5%8D%8E&rft.au=%E6%B2%88%E6%AF%85&rft.au=%E9%AD%8F%E7%85%9C%E7%A8%8B&rft.date=2016&rft.pub=%E4%B8%8A%E6%B5%B7%E4%BA%A4%E9%80%9A%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E4%B8%8A%E6%B5%B7%E8%83%B8%E7%A7%91%E5%8C%BB%E9%99%A2%2C%E4%B8%8A%E6%B5%B7%2C200030%25%E4%B8%AD%E5%B1%B1%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E5%B9%BF%E5%B7%9E%2C510060%25266001%E9%9D%92%E5%B2%9B%E5%A4%A7%E5%AD%A6%E5%8C%BB%E5%AD%A6%E9%99%A2%E9%99%84%E5%B1%9E%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%25%E5%A4%8D%E6%97%A6%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E4%B8%AD%E5%B1%B1%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E4%B8%8A%E6%B5%B7%2C200032%25%E5%A4%A9%E6%B4%A5%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E6%80%BB%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E5%A4%A9%E6%B4%A5%2C300052%25610041%E6%88%90%E9%83%BD%EF%BC%8C%E5%9B%9B%E5%B7%9D%E7%9C%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%EF%BC%8C%E9%A9%AC%E5%8F%AF%25%E7%A6%8F%E5%BB%BA%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E5%8D%8F%E5%92%8C%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E7%A6%8F%E5%B7%9E%2C350001%25%E5%AE%89%E5%BE%BD%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%B8%80%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E5%90%88%E8%82%A5%2C230022%25%E9%83%91%E5%B7%9E%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E9%83%91%E5%B7%9E%2C450008%25%E5%8C%97%E4%BA%AC%E5%A4%A7%E5%AD%A6%E9%99%84%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E5%8C%97%E4%BA%AC%2C100142%25%E9%95%BF%E6%B5%B7%E5%8C%BB%E9%99%A2%E8%83%B8%E5%BF%83%E5%A4%96%E7%A7%91%2C%E4%B8%8A%E6%B5%B7%2C200433%25%E8%BE%BD%E5%AE%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E6%B2%88%E9%98%B3%2C110042%25%E5%90%89%E6%9E%97%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%B8%80%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E9%95%BF%E6%98%A5%2C130021%25%E5%9B%9B%E5%B7%9D%E5%A4%A7%E5%AD%A6%E5%8D%8E%E8%A5%BF%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E6%88%90%E9%83%BD%2C610041%25%E5%A4%8D%E6%97%A6%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E5%8D%8E%E5%B1%B1%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E4%B8%8A%E6%B5%B7%2C200032%25%E5%A4%A9%E6%B4%A5%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E9%A3%9F%E7%AE%A1%E7%99%8C%E4%B8%AD%E5%BF%83%2C%E5%A4%A9%E6%B4%A5%2C300060%25%E6%B5%99%E6%B1%9F%E7%9C%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E6%9D%AD%E5%B7%9E%2C310022%25%E6%B1%9F%E8%A5%BF%E7%9C%81%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2%E8%83%B8%E5%A4%96%E7%A7%91%2C%E5%8D%97%E6%98%8C%2C330006&rft.issn=1009-3419&rft.volume=19&rft.issue=7&rft.spage=459&rft.epage=464&rft_id=info:doi/10.3779%2Fj.issn.1009-3419.2016.07.08&rft.externalDocID=zgfazz201607009
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91098A%2F91098A.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgfazz%2Fzgfazz.jpg